PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER (calcium chloride)
Prismasol B22GK 4/
How PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER Works
This injection works by supplying key ions like sodium, potassium, and calcium to regulate water distribution and nerve conduction throughout the body. These electrolytes facilitate essential functions such as muscle contraction, blood clotting, and protein synthesis while maintaining the body's acid-base balance. By replenishing these components, the solution supports normal cardiac function and the structural framework of bones and teeth.
Details
- Status
- Prescription
- First Approved
- 2006-10-25
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
Companies
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER Approval History
What PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER Treats
2 indicationsPRISMASOL B22GK 4/0 IN PLASTIC CONTAINER is approved for 2 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Water deficiency
- Electrolyte imbalance
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER
3 of 18FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
7 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07550413 | 20042026 | Ph 2 | not yet recruiting | Role of Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Section |
| NCT03772990 ICARUS | 21/2019 | Ph 4 | completed | Calcium Administration in Cardiac Surgery |
| NCT05027048 CALBLOC results posted | 62206 MRTG-02-15-2022-Ansari, YIG-2020 | Ph 3 | completed | Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery |
| NCT04153435 COCA results posted | 00002 2019-003387-46 | Ph 2 | completed | Calcium for Out-of-Hospital Cardiac Arrest |
| NCT03867383 results posted | 43076 | Ph 1, Ph 2 | completed | Calcium Chloride for Prevention of Uterine Atony During Cesarean |
| NCT01941914 | AA1310 | Ph 1 | completed | Calcium Electroporation for the Treatment of Keloids |
| NCT00955266 results posted | 2009-P-000052 | Ph 4 | terminated | A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER FDA Label Details
Indications & Usage
FDA Label (PDF)PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER is indicated for the treatment of Water deficiency; Electrolyte imbalance.
Track PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.